0.1301
0.08%
-0.0001
Pre-market:
.131
0.0009
+0.69%
Zomedica Corp stock is currently priced at $0.1301, with a 24-hour trading volume of 1.35M.
It has seen a -0.08% decreased in the last 24 hours and a -2.62% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.1307 pivot point. If it approaches the $0.1285 support level, significant changes may occur.
Previous Close:
$0.1302
Open:
$0.129
24h Volume:
1.35M
Market Cap:
$127.49M
Revenue:
$25.19M
Net Income/Loss:
$-34.53M
P/E Ratio:
-5.6565
EPS:
-0.023
Net Cash Flow:
$-20.62M
1W Performance:
+0.62%
1M Performance:
-2.62%
6M Performance:
-16.60%
1Y Performance:
-32.24%
Zomedica Corp Stock (ZOM) Company Profile
Name
Zomedica Corp
Sector
Phone
734-369-2555
Address
100 Phoenix Drive, Suite 190, Ann Arbor, MI
Zomedica Corp Stock (ZOM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-06-23 | Initiated | Dawson James | Buy |
Zomedica Corp Stock (ZOM) Financials Data
Zomedica Corp (ZOM) Revenue 2024
ZOM reported a revenue (TTM) of $25.19 million for the quarter ending December 31, 2023, a +33.05% rise year-over-year.
Zomedica Corp (ZOM) Net Income 2024
ZOM net income (TTM) was -$34.53 million for the quarter ending December 31, 2023, a -102.96% decrease year-over-year.
Zomedica Corp (ZOM) Cash Flow 2024
ZOM recorded a free cash flow (TTM) of -$20.62 million for the quarter ending December 31, 2023, a -62.42% decrease year-over-year.
Zomedica Corp (ZOM) Earnings per Share 2024
ZOM earnings per share (TTM) was -$0.036 for the quarter ending December 31, 2023, a -111.76% decline year-over-year.
About Zomedica Corp
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Cap:
|
Volume (24h):